
|Articles|March 14, 2014
Euro Medicines Agency Updates List of Tenders
On March 13, the European Medicines Agency published updated information about current tenders...
Advertisement
On March 13, the European Medicines Agency (EMA) published updated information about current tenders—documents that explain a project and its requirements to intending bidders—worth more than £60,000 ($99,700).
The newest tender to be unveiled consists of a contract worth 1.2 million euros for the provision of information resources at the Agency itself. The closing date is June 4, 2014.
Further details about the latest tenders—which typically contain a notice inviting tenders, instructions to bidders, the conditions, form of submission, and bill of quantities—are available via this link:
Advertisement
Related to this article

In this video interview, Shaalan Beg, MD, MBA, FASCO, chief medical officer at ConcertAI, outlines how integrating trial matching with standard of care workflows and uniform screening can replace reliance on physician memory with timely, consistent nudges.

In today’s ACT Brief, we examine why oncologists should lead trial discussions while AI supports patients, how site burden can be measured before it becomes risk, and how FDA approved Cosentyx and Wilserdly for two different conditions.

Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.

In this video interview, Shaalan Beg, MD, MBA, FASCO, chief medical officer at ConcertAI, makes the case that oncologists must lead discussions about randomization and treatment decisions, while AI can prepare patients beforehand and support them afterward.

In today’s ACT Brief, we examine how AI can cut coordinator screening time, how participants respond to AI-assisted pre-screening, and how FDA approved three new treatments.

Participants in a survey of 354 pre-screening respondents rated AI voice-assisted screening (Clara) favorably and were more likely to schedule and attend study appointments than web-form users, though self-selection means the association cannot be read as causal.

In this video interview, Shaalan Beg, MD, MBA, FASCO, chief medical officer at ConcertAI, explains how AI can unlock unstructured chart data and cut coordinator screening time from hours to minutes, easing a clinical research workforce under strain.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where AI Helps in Patient Conversations About Trials and Where Humans Must Lead
2
Participant Experience with AI-Assisted and Web-Based Clinical Trial Pre-Screening
3
ACT Brief: AI-Driven Coordinator Screening, Participant Pre-Screening Perceptions, and Three New FDA Approvals
4
Measuring Burden Before It Becomes Risk: Coordinator Friction, Tool Fatigue, and Trial Quality
5
